Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [email protected]

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | [email protected]
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
12:20a ALARA RESOURCES : Quarterly Activities and Cashflow Reports
12:15a MUSTANG RESOURCES : Quarterly Report & Appendix 5B
12:15a FIJI SUGAR : Appointment of Chief Financial Officer (CFO)
12:15a COCHLEAR : Change in substantial holding
04/30 SPORTING C D PORTUGAL : Sp. Braga, 2-Sporting CP, 3
04/30 Lake Ontario shoreline property owners watch property wash away
04/30 MERIDIAN ENERGY : commits to converting 50% of its fleet to electric vehicles by June 2018
04/30 GENESIS ENERGY : Q3 2017 Performance Report
04/30 SEMAFO : Changed Number of Shares and Votes in SEMAFO
04/30 GENESIS ENERGY : acquisition of Nova Energy LPG Business
Latest news
Advertisement
Hot News 
5.97%REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects for eczema drug
5.37%AIR BERLIN : Restructuring costs drive Air Berlin to record loss
3.71%Google parent Alphabet's profit up 29 percent on strong ad sales
-3.42%INTEL : revenue misses estimates as data centre growth slows
-4.06%Baidu's Finance Chief to Lead Investment Firm Baidu Capital -- Update
Most Read News
06:15p COCHLEAR : Change in substantial holding
06:15p MUSTANG RESOURCES : Quarterly Report & Appendix 5B
06:20p ALARA RESOURCES : Quarterly Activities and Cashflow Reports
01:05p Off target in 2016, global elite regroup at Milken conference
04/29 INTERRA RESOURCES : Teen robs man in Walgreens parking lot with toy gun
Most recommended articles
04/27 JPMorgan Chase & Co leaves blockchain consortium R3
04:10pDJAPPLE : Cash Hoard Set to Top $250 Billion
03:48pDJDetroit Auto Makers Are Upbeat as Sales Volumes Stall
02:47p UNITED PARCEL SERVICE : UPS air maintenance workers threaten strike ahead of shareholders meeting
02:41pDJMACY : Bluemercury to Open Manhattan Flagship Store